Last reviewed · How we verify

TS-1 and cisplatin

Taiho Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

TS-1 is a prodrug that is converted into 5-fluorouracil (5-FU) in the body, which is then incorporated into DNA and RNA, interfering with DNA replication and transcription, and cisplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting DNA replication and transcription.

TS-1 is a prodrug that is converted into 5-fluorouracil (5-FU) in the body, which is then incorporated into DNA and RNA, interfering with DNA replication and transcription, and cisplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting DNA replication and transcription. Used for Advanced gastric cancer, Pancreatic cancer.

At a glance

Generic nameTS-1 and cisplatin
SponsorTaiho Pharmaceutical Co., Ltd.
Drug classAntineoplastic agent
TargetDNA
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

TS-1's mechanism of action is primarily through the inhibition of thymidylate synthase, which is necessary for DNA replication. Cisplatin's mechanism of action involves the formation of platinum-DNA adducts, which interfere with DNA replication and transcription, leading to cell death. This results in the inhibition of cancer cell growth and proliferation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: